Oddo BHF Asset Management Sas Buys Shares of 18,224 Labcorp Holdings Inc. $LH

Oddo BHF Asset Management Sas bought a new stake in shares of Labcorp Holdings Inc. (NYSE:LH) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 18,224 shares of the medical research company’s stock, valued at approximately $4,572,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. JPL Wealth Management LLC bought a new stake in shares of Labcorp in the 3rd quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Labcorp in the 4th quarter valued at $26,000. Hilton Head Capital Partners LLC bought a new stake in shares of Labcorp in the 4th quarter valued at $27,000. Eagle Bay Advisors LLC bought a new stake in shares of Labcorp in the 4th quarter valued at $29,000. Finally, Headlands Technologies LLC increased its position in shares of Labcorp by 300.0% in the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock valued at $34,000 after buying an additional 96 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Wall Street Analyst Weigh In

LH has been the subject of a number of research analyst reports. Robert W. Baird set a $334.00 target price on shares of Labcorp in a research note on Friday, May 1st. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Evercore reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Finally, JPMorgan Chase & Co. upped their target price on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Labcorp currently has an average rating of “Moderate Buy” and an average price target of $308.00.

Labcorp Trading Down 0.6%

Labcorp stock opened at $264.61 on Tuesday. Labcorp Holdings Inc. has a one year low of $241.81 and a one year high of $293.72. The company has a market cap of $21.70 billion, a price-to-earnings ratio of 23.44, a P/E/G ratio of 1.86 and a beta of 0.90. The firm has a 50-day moving average of $262.46 and a 200-day moving average of $265.74. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54.

Labcorp (NYSE:LH) last issued its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same period last year, the business posted $3.84 EPS. Labcorp’s revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, equities analysts expect that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Investors of record on Friday, May 29th were paid a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.1%. The ex-dividend date was Friday, May 29th. Labcorp’s dividend payout ratio (DPR) is 25.51%.

Insider Activity

In related news, EVP Kathryn W. Kyle sold 762 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $263.89, for a total value of $201,084.18. Following the completion of the sale, the executive vice president directly owned 3,813 shares in the company, valued at approximately $1,006,212.57. This trade represents a 16.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 5,903 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the completion of the sale, the chief executive officer owned 107,234 shares of the company’s stock, valued at $27,291,053. This trade represents a 5.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.84% of the company’s stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.